LOW-VOLUME · MALE-LED
alfuzosin Side Effects
alfuzosin (also sold as Uroxatral) is a LOW-VOLUME FAERS extract #452 of 524 by FAERS report count. Still opens on MALE-LED: 3% of sex-coded reports are female (66 F / 1,919 M).
Data updated 2026-05-15
- 2,222
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
alfuzosin reporting skew - 3% of sex-coded reports are female (66 F / 1,919 M). Volume band LOW-VOLUME #452 of 524 by FAERS report count; caseload SIGNAL.
Thinner FAERS extract for alfuzosin (Uroxatral) (2,222 reports #452 of 524 by FAERS report count). 3% of sex-coded reports are female (66 F / 1,919 M). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2004–2025). Stamps SIGNAL · DEATH-HEAVY · HOSP-HEAVY · MALE-LED.
DYSPNOEA leads 89 of 2,222 reports
MALE-LED reporters · age peak 75+
Male-led reporters (97% of sex-coded rows)
Age peak 75+ (736 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (212 reports, 9.5%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 52 |
| GASTROINTESTINAL HAEMORRHAGE | 17 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 15 |
| TOXIC EPIDERMAL NECROLYSIS | 14 |
| FALL | 13 |
| BONE MARROW FAILURE | 12 |
| CARDIO-RESPIRATORY ARREST | 12 |
| ACUTE KIDNEY INJURY | 10 |
| DYSPNOEA | 10 |
| SEPSIS | 10 |
| CARDIAC ARREST | 8 |
| HYPONATRAEMIA | 8 |
| LIVER FUNCTION TEST ABNORMAL | 8 |
| MULTI-ORGAN FAILURE | 8 |
| PNEUMONIA | 8 |
| THROMBOCYTOPENIA | 8 |
| ASTHENIA | 7 |
| ATRIAL FIBRILLATION | 7 |
| INTERSTITIAL LUNG DISEASE | 7 |
| PANCREATITIS ACUTE | 7 |
Reactions in Hospitalization Reports
Hospitalization is HEAVY (1,009, 45.4% of the book). Top reactions in those rows:
| Reaction | Reports |
|---|---|
| DYSPNOEA | 65 |
| ACUTE KIDNEY INJURY | 50 |
| HYPOTENSION | 46 |
| FALL | 43 |
| PNEUMONIA | 42 |
| HYPONATRAEMIA | 41 |
| DRUG INTERACTION | 40 |
| CONFUSIONAL STATE | 34 |
| MALAISE | 34 |
| ANAEMIA | 30 |
| PYREXIA | 30 |
| THROMBOCYTOPENIA | 29 |
| DIARRHOEA | 28 |
| HYPERKALAEMIA | 28 |
| ATRIAL FIBRILLATION | 26 |
| CHOLESTASIS | 25 |
| PRODUCT ADMINISTRATION ERROR | 25 |
How to read alfuzosin FAERS figures (SIGNAL · DEATH-HEAVY · HOSP-HEAVY)
FAERS holds 2,222 voluntary reports linked to alfuzosin (Uroxatral), 2004-2025. Death is listed on 212 (9.5%). Hospitalization appears on 1,009 (45.4%). Top co-reported indication: Product Used For Unknown Indication.
Sparse extract - named reactions and MALE-LED skew still differ by drug; not a complete safety profile.
Read with alfuzosin
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-HEAVY stamps.
ABS(total_reports) peer at 2,229 FAERS cases (Δ 7 heavier vs alfuzosin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-HEAVY · MALE-LED.
ABS(total_reports) peer at 2,254 FAERS cases (Δ 32 heavier vs alfuzosin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-HEAVY · MALE-LED.
ABS(total_reports) peer at 2,179 FAERS cases (Δ 43 lighter vs alfuzosin); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-HEAVY · MALE-LED.
ABS(total_reports) peer at 2,273 FAERS cases (Δ 51 heavier vs alfuzosin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-HEAVY · MALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 52.6 pp vs alfuzosin's DEATH-HEAVY): CASELOAD · HOSP-MID.
alfuzosin stamps DEATH-HEAVY · HOSP-HEAVY; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload SIGNAL and the label guide.